Leap Therapeutics (LPTX) Stock Forecast, Price Target & Predictions
LPTX Stock Forecast
Leap Therapeutics stock forecast is as follows: an average price target of $5.50 (represents a 100.73% upside from LPTX’s last price of $2.74) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
LPTX Price Target
The average price target for Leap Therapeutics (LPTX) is $5.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $5.50 to $5.50. This represents a potential 100.73% upside from LPTX's last price of $2.74.
LPTX Analyst Ratings
According to 3 Wall Street analysts, Leap Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for LPTX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Leap Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 14, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $5.50 | $2.83 | 94.35% | 100.73% |
The latest Leap Therapeutics stock forecast, released on May 14, 2024 by Swayampakula Ramakanth from H.C. Wainwright, set a price target of $5.50, which represents a 94.35% increase from the stock price at the time of the forecast ($2.83), and a 100.73% increase from LPTX last price ($2.74).
Leap Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $5.50 |
| Last Closing Price | $2.74 | $2.74 | $2.74 |
| Upside/Downside | -100.00% | -100.00% | 100.73% |
In the current month, the average price target of Leap Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Leap Therapeutics's last price of $2.74. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 28, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| May 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Nov 14, 2023 | Raymond James | Outperform | Outperform | Hold |
| Nov 11, 2022 | Raymond James | Outperform | Outperform | Hold |
Leap Therapeutics's last stock rating was published by Rodman & Renshaw on Jun 28, 2024. The company Initialise its LPTX rating from "null" to "Buy".
Leap Therapeutics Financial Forecast
Leap Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $375.00 | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K |
| Avg Forecast | $11.73M | $9.67M | $7.60M | $5.53M | - | - | - | $1.50M | $341.00K | $188.75K | $386.00K | $1.44M | $305.00K | $258.33K | $391.67K | $200.00K | $1.30M | $3.00M |
| High Forecast | $11.73M | $9.67M | $7.60M | $5.53M | - | - | - | $1.50M | $409.20K | $188.75K | $386.00K | $1.44M | $305.00K | $258.33K | $391.67K | $200.00K | $1.30M | $3.00M |
| Low Forecast | $11.73M | $9.67M | $7.60M | $5.53M | - | - | - | $1.50M | $272.80K | $188.75K | $386.00K | $1.44M | $305.00K | $258.33K | $391.67K | $200.00K | $1.30M | $3.00M |
| # Analysts | 6 | 12 | 6 | 6 | 7 | 9 | 7 | 6 | 14 | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.26% | 1.23% | 1.45% | 0.96% | 1.88% | 0.29% | 0.13% |
Leap Therapeutics's average Quarter revenue forecast for Mar 22 based on 0 analysts is $188.75K, with a low forecast of $188.75K, and a high forecast of $188.75K. LPTX's average Quarter revenue forecast represents a 50233.33% increase compared to the company's last Quarter revenue of $375.00 (Dec 21).
Leap Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 6 | 6 | 7 | 9 | 7 | 6 | 14 | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | $-12.65M | $-14.27M | $-10.59M | $-10.89M | $-11.12M | $-9.60M | $-9.02M | $-7.11M | $-6.94M | $-6.37M | $-7.02M |
| Avg Forecast | $2.35M | $1.93M | $1.52M | $1.11M | - | - | - | $300.00K | $-8.90M | $-11.64M | $77.20K | $287.00K | $61.00K | $-8.20M | $78.33K | $40.00K | $260.00K | $-4.31M |
| High Forecast | $2.35M | $1.93M | $1.52M | $1.11M | - | - | - | $300.00K | $-7.12M | $-9.32M | $77.20K | $287.00K | $61.00K | $-6.56M | $78.33K | $40.00K | $260.00K | $-3.45M |
| Low Forecast | $2.35M | $1.93M | $1.52M | $1.11M | - | - | - | $300.00K | $-10.68M | $-13.97M | $77.20K | $287.00K | $61.00K | $-9.84M | $78.33K | $40.00K | $260.00K | $-5.18M |
| Surprise % | - | - | - | - | - | - | - | -42.16% | 1.60% | 0.91% | -141.09% | -38.76% | -157.35% | 1.10% | -90.80% | -173.53% | -24.50% | 1.63% |
undefined analysts predict LPTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Leap Therapeutics's previous annual EBITDA (undefined) of $NaN.
Leap Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 6 | 6 | 7 | 9 | 7 | 6 | 14 | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | $-12.10M | $-15.90M | $-10.14M | $-10.79M | $-11.14M | $-9.53M | $-9.13M | $-6.71M | $-7.06M | $-6.52M | $-7.23M |
| Avg Forecast | $-12.62M | $-12.23M | $-12.62M | $-13.11M | $-13.07M | $-19.33M | $-16.43M | $-43.03M | $-8.91M | $-11.41M | $-43.03M | $-43.82M | $-48.51M | $-8.30M | $-34.43M | $-50.08M | $-70.42M | $-4.44M |
| High Forecast | $-12.62M | $-12.23M | $-12.62M | $-13.11M | $-13.07M | $-15.55M | $-16.43M | $-43.03M | $-7.13M | $-9.13M | $-43.03M | $-43.82M | $-48.51M | $-6.64M | $-34.43M | $-50.08M | $-70.42M | $-3.56M |
| Low Forecast | $-12.62M | $-12.23M | $-12.62M | $-13.11M | $-13.07M | $-21.85M | $-16.43M | $-43.03M | $-10.69M | $-13.70M | $-43.03M | $-43.82M | $-48.51M | $-9.96M | $-34.43M | $-50.08M | $-70.42M | $-5.33M |
| Surprise % | - | - | - | - | - | - | - | 0.28% | 1.78% | 0.89% | 0.25% | 0.25% | 0.20% | 1.10% | 0.19% | 0.14% | 0.09% | 1.63% |
Leap Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LPTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Leap Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 6 | 6 | 7 | 9 | 7 | 6 | 14 | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | $2.91M | $3.19M | $2.85M | $2.79M | $2.44M | $2.79M | $2.74M | $2.54M | $2.29M | $2.49M | $2.07M |
| Avg Forecast | $38.93M | $32.07M | $25.21M | $18.36M | - | - | - | $4.98M | $1.13M | $626.20K | $1.28M | $4.76M | $1.01M | $857.04K | $1.30M | $663.52K | $4.31M | $1.27M |
| High Forecast | $38.93M | $32.07M | $25.21M | $18.36M | - | - | - | $4.98M | $1.36M | $626.20K | $1.28M | $4.76M | $1.01M | $857.04K | $1.30M | $663.52K | $4.31M | $1.53M |
| Low Forecast | $38.93M | $32.07M | $25.21M | $18.36M | - | - | - | $4.98M | $905.04K | $626.20K | $1.28M | $4.76M | $1.01M | $857.04K | $1.30M | $663.52K | $4.31M | $1.02M |
| Surprise % | - | - | - | - | - | - | - | 0.58% | 2.82% | 4.55% | 2.18% | 0.51% | 2.76% | 3.20% | 1.95% | 3.45% | 0.58% | 1.63% |
Leap Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 7 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to LPTX last annual SG&A of $2.91M (Dec 22).
Leap Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 6 | 6 | 7 | 9 | 7 | 6 | 14 | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | $-0.11 | $-0.14 | $-0.09 | $-0.10 | $-0.14 | $-0.12 | $-0.12 | $-0.09 | $-0.09 | $-0.12 | $-0.23 |
| Avg Forecast | $-0.32 | $-0.31 | $-0.32 | $-0.34 | $-0.33 | $-0.49 | $-0.42 | $-1.10 | $-1.20 | $-1.00 | $-1.10 | $-1.12 | $-1.24 | $-1.06 | $-0.88 | $-1.28 | $-1.80 | $-2.45 |
| High Forecast | $-0.32 | $-0.31 | $-0.32 | $-0.34 | $-0.33 | $-0.40 | $-0.42 | $-1.10 | $-1.20 | $-1.00 | $-1.10 | $-1.12 | $-1.24 | $-1.06 | $-0.88 | $-1.28 | $-1.80 | $-2.45 |
| Low Forecast | $-0.32 | $-0.31 | $-0.32 | $-0.34 | $-0.33 | $-0.56 | $-0.42 | $-1.10 | $-1.20 | $-1.00 | $-1.10 | $-1.12 | $-1.24 | $-1.06 | $-0.88 | $-1.28 | $-1.80 | $-2.45 |
| Surprise % | - | - | - | - | - | - | - | 0.10% | 0.12% | 0.09% | 0.09% | 0.13% | 0.10% | 0.11% | 0.10% | 0.07% | 0.07% | 0.09% |
According to undefined Wall Street analysts, Leap Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LPTX previous annual EPS of $NaN (undefined).
Leap Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| LPTX | Leap Therapeutics | $2.74 | $5.50 | 100.73% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
LPTX Forecast FAQ
Is Leap Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Leap Therapeutics (LPTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of LPTX's total ratings.
What is LPTX's price target?
Leap Therapeutics (LPTX) average price target is $5.5 with a range of $5.5 to $5.5, implying a 100.73% from its last price of $2.74. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Leap Therapeutics stock go up soon?
According to Wall Street analysts' prediction for LPTX stock, the company can go up by 100.73% (from the last price of $2.74 to the average price target of $5.5), up by 100.73% based on the highest stock price target, and up by 100.73% based on the lowest stock price target.
Can Leap Therapeutics stock reach $4?
LPTX's average twelve months analyst stock price target of $5.5 supports the claim that Leap Therapeutics can reach $4 in the near future.
What are Leap Therapeutics's analysts' financial forecasts?
Leap Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-48.825M (high $-45.044M, low $-51.346M), average SG&A $0 (high $0, low $0), and average EPS is $-1.248 (high $-1.151, low $-1.312). LPTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $34.53M (high $34.53M, low $34.53M), average EBITDA is $6.91M (high $6.91M, low $6.91M), average net income is $-50.566M (high $-50.566M, low $-50.566M), average SG&A $114.57M (high $114.57M, low $114.57M), and average EPS is $-1.292 (high $-1.292, low $-1.292).
Did the LPTX's actual financial results beat the analysts' financial forecasts?
Based on Leap Therapeutics's last annual report (Dec 2021), the company's revenue was $1.5M, which missed the average analysts forecast of $2.38M by -37.09%. Apple's EBITDA was $-40.191M, beating the average prediction of $-7.773M by 417.06%. The company's net income was $-40.587M, missing the average estimation of $-144M by -71.75%. Apple's SG&A was $10.77M, beating the average forecast of $7.91M by 36.10%. Lastly, the company's EPS was $-0.47, missing the average prediction of $-4.52 by -89.60%. In terms of the last quarterly report (Dec 2021), Leap Therapeutics's revenue was $375, missing the average analysts' forecast of $386K by -99.90%. The company's EBITDA was $-10.892M, missing the average prediction of $77.2K by -14208.99%. Leap Therapeutics's net income was $-10.788M, missing the average estimation of $-43.035M by -74.93%. The company's SG&A was $2.79M, beating the average forecast of $1.28M by 118.10%. Lastly, the company's EPS was $-0.0954, missing the average prediction of $-1.1 by -91.33%